The N-terminal peptide of ANXA1 (Ac2-16) also reduces tissue injury by activating Akt in experimental models of cardiac/renal reperfusion injury (35, 36) and non-alcoholic steatohepatitis (37). This evidence concerns the gene ANXA1 and metabolic dysfunction-associated steatohepatitis.